Artenimol
Eurartesim (artenimol) is a small molecule pharmaceutical. Artenimol was first approved as Eurartesim on 2011-10-27. It has been approved in Europe to treat malaria.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
170 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 3 | 10 | 49 | 38 | 23 | 119 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 5 | 10 | 15 | 17 | 17 | 60 |
| Vivax malaria | D016780 | EFO_0007445 | B51 | 2 | 3 | 5 | 3 | 6 | 18 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 4 | 4 | 1 | 9 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 2 | — | 5 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 2 | 1 | — | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 2 | 1 | — | 3 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 2 | — | 1 | — | 3 |
| Parasitic diseases | D010272 | EFO_0001067 | B88 | — | — | — | 1 | 1 | 2 |
| Treatment adherence and compliance | D000074822 | — | — | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asymptomatic diseases | D058070 | — | — | — | — | 1 | — | 2 | 3 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | 1 | 1 | — | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | 2 | — | — | 2 |
| Pregnancy rate | D018873 | — | — | — | — | 2 | — | — | 2 |
| Disease susceptibility | D004198 | — | — | — | — | 1 | — | — | 1 |
| Fever | D005334 | — | R50.9 | — | — | 1 | — | — | 1 |
| Therapeutics | D013812 | — | — | — | — | 1 | — | — | 1 |
| Protozoan infections | D011528 | — | B50-B64 | — | — | 1 | — | — | 1 |
| Reproductive tract infections | D060737 | — | — | — | — | 1 | — | — | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | — | 1 | — | — | 1 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Papillomavirus infections | D030361 | — | — | — | 3 | — | — | — | 3 |
| Squamous intraepithelial lesions | D000081483 | — | — | — | 2 | — | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 1 | 2 |
| Squamous intraepithelial lesions of the cervix | D065310 | — | — | — | 2 | — | — | — | 2 |
| Carcinoma in situ | D002278 | — | D09.9 | 1 | 1 | — | — | — | 2 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Parasitemia | D018512 | — | — | — | 1 | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | — | — | — | 1 |
| Precancerous conditions | D011230 | — | — | — | 1 | — | — | — | 1 |
| Vulvar diseases | D014845 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Combination drug therapy | D004359 | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Uterine cervical neoplasms | D002583 | — | — | 1 | — | — | — | — | 1 |
| Uterine cervical dysplasia | D002578 | EFO_1000910 | N87 | 1 | — | — | — | — | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 1 | — | — | — | — | 1 |
| Alopecia | D000505 | — | L64 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug resistance | D004351 | — | Z16.30 | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | — | — | — | — | 1 | 1 |
| Behavior | D001519 | GO_0007610 | STY/T053 | — | — | — | — | 1 | 1 |
| Angle class ii malocclusion | D008312 | — | M26.212 | — | — | — | — | 1 | 1 |
| Malocclusion | D008310 | — | M26.4 | — | — | — | — | 1 | 1 |
| Chemoprevention | D018890 | — | — | — | — | — | — | 1 | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | — | — | — | 1 | 1 |
| Child nutrition disorders | D015362 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Artenimol |
| INN | artenimol |
| Description | Dihydroartemisinin is a sesquiterpenoid compound which is used as a drug for treatment of malaria. It has a role as an antimalarial. |
| Classification | Small molecule |
| Drug class | antimalarials (artemisin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@@]23OO4 |
Identifiers
| PDB | — |
| CAS-ID | 71939-50-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL252518 |
| ChEBI ID | — |
| PubChem CID | 6918483 |
| DrugBank | — |
| UNII ID | 6A9O50735X (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use